$2.33
-0.02 (-0.85%)
Open$2.36
Previous Close$2.35
Day High$2.36
Day Low$2.31
52W High$3.19
52W Low$1.36
Volume—
Avg Volume859.0K
Market Cap186.93M
P/E Ratio12.19
EPS$0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+1,239.5% upside
Current
$2.33
$2.33
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 53.87M | 52.08M | 361.03M |
| Net Income | -6,746,992 | -5,869,785 | 15.50M |
| Profit Margin | -12.5% | -11.9% | 4.3% |
| EBITDA | -4,123,608 | -3,786,783 | 29.24M |
| Free Cash Flow | — | — | 6.36M |
| Rev Growth | +3.5% | +3.5% | +17.6% |
| Debt/Equity | — | — | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |